ZYUS Life Sciences has received a Cannabis Drug License issued pursuant to the Cannabis Act (Canada) and Cannabis Regulations. This license pertains specifically to its processing facility located in Saskatoon, Saskatchewan, which is dedicated to the manufacture of pharmaceutical-grade cannabinoid formulations.
Advancing Innovation Through Trichomylin® Softgel Capsules Phase 2 Clinical Trial
As previously announced, ZYUS intends to launch a Phase 2 Clinical Trial in Canada later this year to assess the preliminary efficacy, safety, and tolerability of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. ZYUS' receipt of the Cannabis Drug License and compliance with applicable quality guidelines issued by the International Council for Harmonisation and Good Manufacturing Practice standards provides a robust framework respecting the Company's manufacture of Trichomylin® softgel capsules for its Phase 2 Clinical Trial and brings ZYUS one step closer to achieving its goal of obtaining regulatory approval of its proprietary drug product.
In addition to this licensing advancement, ZYUS has also been granted Patent No. 2022/12127 in South Africa respecting its second drug candidate. The South African patent expands ZYUS' robust intellectual property portfolio, which is comprised of multiple patent families focused on fixed-dose cannabinoid-based formulations for pain management and other clinically unmet needs. Issuance of the South African patent, together with the recent issuance of the Company's U.S. patent covering Trichomylin® softgel capsules, underscores ZYUS' dedication to pioneering novel therapies in the pharmaceutical landscape.
"Receipt of the Cannabis Drug License marks a significant milestone for ZYUS," said Brent Zettl, President and CEO of ZYUS. "This achievement, alongside the issuance of the first patent for our second drug candidate in South Africa, positions ZYUS as a leader in the development of innovative therapies, aimed at improving patients' quality of life."
For more information:
Zyus Life Science Corporation
1-888-651-9987
[email protected]
zyus.com